Recently, the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) announced that Encorafenib has been provisionally approved for priority review. It will be used in combination with cetuximab and the FOLFOX chemotherapy regimen as a first-line treatment for adult patients with BRAF V600E-mutant metastatic colorectal cancer.
This marks a significant therapeutic advancement in the international medical community for this difficult-to-treat cancer driven by a specific genetic mutation.
**What is Encorafenib and why is it important?**
Encorafenib is a highly selective, ATP-competitive small-molecule BRAF inhibitor. In simple terms, it precisely targets tumor cells carrying the BRAF V600E mutation, inhibiting their growth and proliferation. Compared to some earlier approved BRAF inhibitors, Encorafenib has longer pharmacodynamic activity, meaning it remains effective in the body for a more extended period.
**Clinical Data: Evidence of Breakthrough Efficacy**
On January 25, 2025, *Nature Medicine* published the Phase 3 clinical study of Encorafenib + Cetuximab + chemotherapy for the treatment of BRAF-mutant colorectal cancer. The BREAKWATER study (NCT04607421) aimed to evaluate the efficacy of encorafenib plus cetuximab with or without standard chemotherapy in patients with BRAF V600E-mutant colorectal cancer. A total of 236 patients were randomized to the experimental group and 243 to the control group. Results showed a confirmed objective response rate (cORR) of 60.9% in the experimental group, with 3 patients achieving complete response (CR), 64 partial response (PR), and 31 stable disease (SD). In the control group, cORR was 40.0%, with 2 CR, 42 PR, and 34 SD. Median duration of response (DOR) was 13.9 months and 11.1 months, respectively. Median overall survival was not estimable in the experimental group, compared to 14.6 months in the control group.
**For International Patients: Beijing South Region Oncology Hospital International Department Provides Access to Cutting-Edge Treatment**
This advanced treatment regimen has now entered the priority review pathway in China. For international patients—if you or a family member is seeking better treatment options—the Beijing South Region Oncology Hospital International Department is committed to serving as a bridge to global advanced medical technology. We closely follow international drug developments and offer professional consultations and medical assistance to eligible patients.
**Contact Us Today to Begin Your Journey of Hope**
Don’t wait. Every treatment opportunity has the potential to change the course of life. Our multilingual service team is ready to provide consultation, appointment scheduling, and medical guidance.
��� Priority Hotline: 400-880-3716
��� WeChat Instant Contact: ID: 17801183037
��� Email:
- Primary: `100085_010@163.com`
- Backup: `myimmnet@163.com`
You can reach us through any of the above channels. Our international patient coordinators will respond promptly to assist with medical records organization, treatment option evaluation, and any questions about seeking care in Beijing. The Beijing South Region Oncology Hospital International Department stands ready to face the challenges with you, with professionalism and compassion.
Post time: Apr-23-2026